Pediatric and adolescent medicine· 2013· Book chapter
Hematological Problems in Pediatric Intensive Care
- 3,517citations
- 2013year
Short summary
Desmopressin (DDAVP) has been a safe and cost-effective treatment for children with von Willebrand disease and Hemophilia A for nearly 35 years, significantly reducing exposure to plasma-derived products.
AI-generated from the title and abstract; the full text is not read.
Key points
- DDAVP has been used for ~35 years in children with VWD and Hemophilia A.
- Treatment with DDAVP significantly reduces the need for plasma-derived products.
- DDAVP has a good safety profile and is very low cost.
- Response to DDAVP depends on age, baseline factor levels, and genetic mutations.
- DDAVP is also used for platelet function defects and other bleeding tendencies.
AI-generated from the title and abstract; the full text is not read.
Abstract
Desmopressin (1-deamino-8-D-arginine vasopressin, DDAVP) has been used in children with von Willebrand disease (VWD) and Hemophilia A for almost 35 years. This treatment has substantially lowered the number of children exposed to human plasma derived products, with a good safety profile, and at very low cost. The response to DDAVP has been shown to be associated with age, baseline factor level, and genetic mutations. A DDAVP challenge test is recommended. DDAVP has also been used to prevent and treat bleeding episodes in children with platelet function defects and other disorders associated with bleeding tendency.
The authors' abstract, as published at the source. Pediatric and adolescent medicine, 2013 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hematology
HematologyMedicine